Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency
- 19 March 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 315 (4) , 808-814
- https://doi.org/10.1016/j.bbrc.2004.01.125
Abstract
No abstract availableKeywords
Funding Information
- Takeda Science Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Health Sciences Foundation (KH63124)
This publication has 22 references indexed in Scilit:
- Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdvanced Drug Delivery Reviews, 2003
- Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivityNature Biotechnology, 2003
- Synthesis of a poly(vinylpyrrolidone-co -dimethyl maleic anhydride) co-polymer and its application for renal drug targetingNature Biotechnology, 2003
- Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeabilityJournal of Clinical Investigation, 2002
- Raster3D Version 2.0. A program for photorealistic molecular graphicsActa Crystallographica Section D-Biological Crystallography, 1994
- A phase I study of local treatment of liver metastases with recombinant tumour necrosis factorEuropean Journal Of Cancer, 1992
- Phase I study of intratumoral application of recombinant human tumor necrosis factorEuropean Journal of Cancer and Clinical Oncology, 1989
- Phase I clinical trial of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Phase I study of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987